Study of Biomarkers to Predict and Monitor Treatment in Adults with Mycosis Fungoides and Szary Syndrome

What this Trial Is About

Researchers are conducting an observational study to identify prognostic and treatment-predictive biomarkers in patients with Mycosis fungoides and Se9zary syndrome. These are types of lymphoma affecting the skin, and the study aims to better understand how blood and skin markers relate to disease progression and treatment response. The study is sponsored by Lund University Hospital and includes both patients and healthy volunteers for comparison. Participants will undergo regular blood tests and skin analyses to study the lymphoma microenvironment, skin barrier, and microbiology profile. These samples are collected systematically from the start of the study through up to three years. Treatments for participants continue as per standard clinical care, without alteration for the study. During the study visits at baseline and at months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36, blood samples and skin assessments are performed to track protein markers, immune profiles, epigenetic changes, and skin characteristics. Researchers will measure these markers repeatedly over time to understand their role in disease outcomes. Participants will be monitored throughout the study period, which may last up to three years.

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.